Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response
Authors:
- Carsten HagemannCHCarsten Hagemann
- Nikolas NeuhausNNNikolas Neuhaus
- Mathias DahlmannMDMathias Dahlmann
- Almuth F. KesslerAKAlmuth F. Kessler
- Dennis KobeltDKDennis Kobelt
- Pia HerrmannPHPia Herrmann
- Matthias EyrichMEMatthias Eyrich
- Benjamin FreitagBFBenjamin Freitag
- Thomas LinsenmannTLThomas Linsenmann
- Camelia M. MonoranuCMCamelia M. Monoranu
- Ralf-Ingo ErnestusRERalf-Ingo Ernestus
- Mario LöhrMLMario Löhr
Open Access
Abstract
Glioblastoma multiforme is the most aggressive primary brain tumor of adults, but lacks reliable and liquid biomarkers. We evaluated circulating plasma transcripts of metastasis-associated in colon cancer-1 (MACC1), a prognostic biomarker for solid cancer entities, for prediction of clinical outcome and therapy response in glioblastomas. MACC1 transcripts were significantly higher in patients compared to controls. Low MACC1 levels clustered together with other prognostically favorable markers. It was associated with patients’ prognosis in conjunction with the isocitrate dehydrogenase (IDH) mutation status: IDH1 R132H mutation and low MACC1 was most favorable (median overall survival (OS) not yet reached), IDH1 wildtype and high MACC1 was worst (median OS 8.1 months), while IDH1 wildtype and low MACC1 was intermediate (median OS 9.1 months). No patients displayed IDH1 R132H mutation and high MACC1. Patients with low MACC1 levels receiving standard therapy survived longer (median OS 22.6 months) than patients with high MACC1 levels (median OS 8.1 months). Patients not receiving the standard regimen showed the worst prognosis, independent of MACC1 levels (low: 6.8 months, high: 4.4 months). Addition of circulating MACC1 transcript levels to the existing prognostic workup may improve the accuracy of outcome prediction and help define more precise risk categories of glioblastoma patients.Keywords
Funding Information
- German Cancer Consortium (DKTK), Heidelberg, Germany (DKTK)
- Deutsche Forschungsgemeinschaft (Open Access Publishing)
This publication has 56 references indexed in Scilit:
- Epigenetic Silencing of miR-338-3p Contributes to Tumorigenicity in Gastric Cancer by Targeting SSX2IPPLOS ONE, 2013
- Circulating MACC1 Transcripts in Colorectal Cancer Patient Plasma Predict Metastasis and PrognosisPLOS ONE, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic CorrelationsClinical Cancer Research, 2011
- Diagnostic and Prognostic Value of Metastasis Inducer S100A4 Transcripts in Plasma of Colon, Rectal, and Gastric Cancer PatientsThe Journal of Molecular Diagnostics, 2011
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1αScience, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005